![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » High Court Refuses to Hear Case on Six-Month Wait for Biosimilar Launch
High Court Refuses to Hear Case on Six-Month Wait for Biosimilar Launch
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/gavel_on_stethoscope.jpg?t=1433941190&width=430)
December 16, 2016
The U.S. Supreme Court has refused to hear a case on whether biosimilar makers must wait six months after receiving FDA approval to bring a product to market.
The high court denied a petition from Apotex to overturn a federal appeals court ruling that that says biosimilar makers must give reference product holders six months’ notice before going to market. This particular case involves the launch of a biosimilar version of Amgen's Neulasta.
The refusal lets stand a Federal Circuit decision that says the 180-day notification required by federal law must come after a company secures FDA approval.
Upcoming Events
-
21Oct